These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17921917)

  • 1. Non-Hodgkin's lymphomas: immunologic prognostic studies.
    Hadzi-Pecova L; Petrusevska G; Stojanovic A
    Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
    Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
    Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
    Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
    Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applicability of international prognostic index in non Hodgkin's lymphoma in Pakistan.
    Aziz Z; Sana S; Saeed S; Akram M
    J Ayub Med Coll Abbottabad; 2004; 16(2):15-20. PubMed ID: 15455610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
    Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
    Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
    Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
    Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
    Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.
    Terol MJ; López-Guillermo A; Bosch F; Villamor N; Cid MC; Rozman C; Campo E; Montserrat E
    J Clin Oncol; 1998 Jan; 16(1):35-40. PubMed ID: 9440720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
    Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
    PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Sasaki K; Umeda M
    Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
    Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.